Chengdu Hanchen Guangyi Technology

About Chengdu Hanchen Guangyi Technology

Chengdu Hanchen Guangyi Technology Co., Ltd. (also known as HC Scientific) operates as a life sciences intelligent automation company, providing integrated solutions for the sector. Founded in December 2015 by Dr. Zhang Han, a returning overseas scholar, the company is headquartered in Chengdu's Tianfu International Bio-town. Dr. Zhang returned to his hometown of Chengdu to establish the firm, leveraging his background from a top international optical center to address the domestic market. The founding team was composed of technical experts from the U.S., seasoned managers, and R&D specialists from prominent Chinese universities.

The firm focuses on developing and producing high-throughput, automated molecular detection equipment. Its business model is centered on the research, development, production, and sale of biomedical systems and instruments, aiming to serve a global clientele in life sciences. Key markets include modern agriculture (specifically molecular breeding), in-vitro diagnostics, and scientific research. By providing automated tools, the company seeks to reduce complex manual operations for researchers and scientists, thereby lowering costs and improving efficiency. Its clientele ranges from large-scale research institutions and third-party testing centers to agricultural breeding companies.

HC Scientific's core offering is a suite of intelligent, automated life science tools and platforms. A notable product is the Gene Matrix system, a high-throughput, automated molecular detection platform with proprietary intellectual property. The company also offers automated nucleic acid extraction systems (H9600, MagC 9600), an automatic nucleic acid concentration analysis and normalization workstation (MetricAnalyzer 3430S), a real-time PCR system (Techcycler 384Q), and a high-throughput tissue grinder (TurboGrinder 5760). These products are designed to address bottlenecks in processes like genetic screening and analysis by offering high-throughput, low-cost solutions, which has been particularly relevant in scenarios requiring large-scale screening. A key achievement was the successful development of products that broke the reliance on imported equipment in the molecular breeding field in China.

The company's journey has been marked by significant financial milestones, including an angel round in 2017, a Series A in 2018, a Series A+ in 2020, a Series B in 2021, and a substantial Series B+ round in 2023 that raised over 300 million RMB. This consistent attraction of capital from prominent investors like Legend Capital, LYFE Capital, and Fosun Group underscores market confidence in its strategy and technological capabilities.